MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Selexipag

CAS No. : 475086-01-2

MCE 国际站：Selexipag

产品活性：Selexipag (NS-304) 是一种口服有效的 前列环素 (PGI₂) 受体激动剂。

研究领域：GPCR/G Protein

作用靶点：Prostaglandin Receptor

In Vitro: Selexipag (NS-304) is an orally available and long-acting IP receptor agonist prodrug, and its active form, MRE-269, is highly selective for the IP receptor. Selexipag (NS-304) inhibits the binding of [³H]Iloprost to the human and rat IP receptors in a concentration-dependent manner. The K_i is 260 nM for the human IP receptor and 2100 nM for the rat IP receptor. The intracellular cAMP levels in hIP-CHO cells are increased in a concentration-dependent manner by treatment with Selexipag (NS-304) with EC₅₀ of 177nM. Selexipag (NS-304) also inhibits platelet aggregation in humans and monkeys with IC₅₀ values of 5.5 and 3.4 μM, respectively, but it shows no inhibition in dogs (IC₅₀ of >100 μM).

In Vivo: The C_max of MRE-269 after oral administration of NS-304 is 1.1 μg/mL in rats and 9.0 μg/mL in dogs. Selexipag (NS-304) at 1 or 3 mg/kg increases FSBF in anesthetized rats for more than 4 h after intraduodenal administration in a dose-dependent manner. In particular, Selexipag (NS-304) at 3 mg/kg causes a sustained increase in FSBF and exhibits a maximal increase of 93% in FSBF 1 h after administration.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Endocrinology Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Angiogenesis-Related Compound Library  |  Rare Diseases Drug Library  |  Children’s Drug Library  |  EMA-Approved Drug Library  |  Human Metabolite Library  |  Coagulation and Anti-coagulation Compound Library  |  Off-patent Drug Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Highly Selective Activators Library  |  CAY10580  |  EP3 antagonist 3  |  Dinoprost-d₄  |  TCS 2510  |  Vidupiprant  |  EP2 receptor antagonist-1  |  FR181157  |  SC 51089  |  SC-51322  |  Misoprostol acid  |  Treprostinil sodium  |  Aganepag isopropyl  |  Prostaglandin E2  |  Taprostene  |  Cicaprost  |  Fevipiprant  |  Carboprost  |  TG6-10-1  |  Latanoprost acid  |  Carbacyclin  |  KW-8232 free base  |  Nocloprost  |  Cloprostenol isopropyl ester  |  ICI 192605  |  HHS-0701  |  Bimatoprost-d₅  |  AS604872

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。